Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.58 |
| ▸ | HTR2B | P41595 | 2/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.58 |
| ▸ | DRD3 | P35462 | 1/20 | 0.58 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.58 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.56 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.54 |
| ▸ | HTR2C | P28335 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.51 |
| ▸ | IDO1 | P14902 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4239980 | 0.89 | DPP7 (0.59) | HTR2AHTR2BSIGMAR1LMNAMAPT | |
| SCHEMBL4245054 | 0.86 | SCN8A (0.60) | HTR2AHTR2BSIGMAR1LMNAMAPT | |
| SCHEMBL13972842 | 0.86 | KDM4E (0.52) | HTR2AHTR2BSIGMAR1LMNAMAPT | |
| SCHEMBL17664610 | 0.84 | BCHE (0.51) | HTR2AHTR2BSIGMAR1LMNAMAPT | |
| SCHEMBL4245195 | 0.84 | DPP7 (0.55) | HTR2AHTR2BMAPTSCN8ADPP7 | |
| SCHEMBL4235847 | 0.83 | SCN8A (0.65) | HTR2AHTR2BSIGMAR1LMNAMAPT | |
| SCHEMBL13972872 | 0.83 | CYP19A1 (0.66) | LMNAMAPTMEN1KMT2ACYP1A2 | |
| SCHEMBL4238709 | 0.82 | SCN8A (0.64) | HTR2AHTR2BSIGMAR1LMNAMAPT | |
| SCHEMBL24455109 | 0.82 | DPP7 (0.54) | HTR2AHTR2BSIGMAR1LMNAMAPT | |
| SCHEMBL5227682 | 0.82 | DPP7 (0.57) | HTR2AHTR2BSCN8ADPP7HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1451160-B1 | PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN | ICAGEN INC (US) | 2010-01-13 | — | — | EP | claimed |
| EP-4293009-B1 | FENFLURAMINE COMPOSITIONS AND METHODS OF PREPARING THE SAME | ZOGENIX INTERNATIONAL LTD (GB) | 2025-06-11 | — | — | EP | disclosed |
| EP-3800177-B1 | FENFLURAMINE COMPOSITIONS AND METHODS OF PREPARING THE SAME | ZOGENIX INTERNATIONAL LTD (GB) | 2025-01-29 | — | — | EP | disclosed |
| EP-4139308-B1 | PURINE DERIVATIVES AS DRUGS FOR THE TREATMENT OF NEONATAL HYPOXIA-ISCHEMIA BRAIN INJURY AND RELATED DISEASES | COMMISSARIAT ENERGIE ATOMIQUE (FR) | 2024-07-17 | — | — | EP | disclosed |
| EP-4293009-A2 | FENFLURAMINE COMPOSITIONS AND METHODS OF PREPARING THE SAME | Zogenix International Limited (GB) | 2023-12-20 | — | — | EP | disclosed |
| US-11634377-B2 | Fenfluramine compositions and methods of preparing the same | ZOGENIX INTERNATIONAL LIMITED (GB) | 2023-04-25 | — | — | US | disclosed |
| CN-113499330-A | Fenfluramine composition and preparation method thereof | 周格尼克斯国际有限公司 | 2021-10-15 | — | — | CN | disclosed |
| CN-108883399-B | Fenfluramine composition and preparation method thereof | 周格尼克斯国际有限公司 | 2021-06-22 | — | — | CN | disclosed |
| US-20210147335-A1 | FENFLURAMINE COMPOSITIONS AND METHODS OF PREPARING THE SAME | ZOGENIX INTERNATIONAL LIMITED (GB) | 2021-05-20 | — | — | US | disclosed |
| US-20210147335-A1 | FENFLURAMINE COMPOSITIONS AND METHODS OF PREPARING THE SAME | ZOGENIX INTERNATIONAL LIMITED (GB) | 2021-05-20 | — | — | US | disclosed |
| WO-2017112702-A1 | FENFLURAMINE COMPOSITIONS AND METHODS OF PREPARING THE SAME | ZOGENIX INTERNATIONAL LIMITED (GB) | 2017-06-29 | — | — | WO | disclosed |
| WO-2017112702-A1 | FENFLURAMINE COMPOSITIONS AND METHODS OF PREPARING THE SAME | ZOGENIX INTERNATIONAL LIMITED (GB) | 2017-06-29 | — | — | WO | disclosed |
| US-20170174613-A1 | FENFLURAMINE COMPOSITIONS AND METHODS OF PREPARING THE SAME | ZOGENIX INTERNATIONAL LIMITED (GB) | 2017-06-22 | — | — | US | disclosed |
| US-20170174613-A1 | FENFLURAMINE COMPOSITIONS AND METHODS OF PREPARING THE SAME | ZOGENIX INTERNATIONAL LIMITED (GB) | 2017-06-22 | — | — | US | disclosed |
| US-20090137653-A1 | SUBSTITUTED BENZYLAMINES AS CYP2A INHIBITORS AND USES THEREOF TO TREAT NICOTINE DEPENDENCE | INFLAYZME PHARMACEUTICALS LTD. (CA) | 2009-05-28 | — | — | US | disclosed |
| US-7504391-B2 | Selective D1/D5 receptor antagonists for the treatment of obesity and CNS disorders | SCHERING CORPORATION (US) | 2009-03-17 | — | — | US | disclosed |
| EP-1871357-A2 | SUBSTITUTED BENZYLAMINES AS CYP2A INHIBITORS AND USES THEREOF TO TREAT NICOTINE DEPENDENCE | Inflazyme Pharmaceuticals, Ltd. (CA) | 2008-01-02 | — | — | EP | disclosed |
| US-20070293511-A1 | Crf Receptor Antagonists and Methods | SB PHARMCO PUERTO RICO INC. AND NEUROCRINE BIOSCIENCES, INC., A CORPORATION | 2007-12-20 | — | — | US | disclosed |
| US-7247725-B2 | Gamma-aminoamide modulators of chemokine receptor activity | MERCK & CO., INC. (US) | 2007-07-24 | — | — | US | disclosed |
| WO-2006108149-A2 | SUBSTITUTED BENZYLAMINES AS CYP2A INHIBITORS AND USES THEREOF TO TREAT NICOTINE DEPENDENCE | INFLAZYME PHARMACEUTICALS LTD. (CA) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147335-A1 | FENFLURAMINE COMPOSITIONS AND METHODS OF PREPARING THE SAME | FAAH, FAAH2, TPH1 | HTR2A 34/4885HTR2B 35/4885SIGMAR1 1220/4885 |
| US-20070293511-A1 | Crf Receptor Antagonists and Methods | CRHR1, CRHR2, CRH | HTR2A 26/4885HTR2B 46/4885SIGMAR1 299/4885 |
| US-11634377-B2 | Fenfluramine compositions and methods of preparing the same | FAAH, FAAH2, TPH1 | HTR2A 34/4885HTR2B 35/4885SIGMAR1 1220/4885 |
| US-20170174613-A1 | FENFLURAMINE COMPOSITIONS AND METHODS OF PREPARING THE SAME | FAAH, FAAH2, TPH1 | HTR2A 34/4885HTR2B 35/4885SIGMAR1 1220/4885 |
| US-20090137653-A1 | SUBSTITUTED BENZYLAMINES AS CYP2A INHIBITORS AND USES THEREOF TO TREAT NICOTINE DEPENDENCE | CYP2A6, CYP2B6, CYP2D6 | HTR2A 192/4885HTR2B 311/4885SIGMAR1 684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.